Information Provided By: 
Fly News Breaks for June 30, 2015
JUNO, CELG, LBIO
Jun 30, 2015 | 08:59 EDT
After Celgene (CELG) announced that it would collaborate with Juno Therapeutics (JUNO) for access to CAR- T therapies, Roth Capital says the deal bodes well for Lion Biotechnologies (LBIO). The firm says that the deal draws attention to T-cells, where Lion is poised to achieve differentiation, according to the firm. Roth believes that T-cell therapy is safer than CAR T and has significant potential in melanoma and HPV-related cancers. Roth reiterates a $17 price target and Buy rating on Lion.
News For LBIO;CELG;JUNO From the Last 2 Days
There are no results for your query LBIO;CELG;JUNO
